Spots Global Cancer Trial Database for ret gene mutation

Every month we try and update this database with for ret gene mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)	NCT04222972	RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv...	Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel	18 Years -	Hoffmann-La Roche
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC	NCT06109558	Non Small Cell ... RET Gene Mutati... MET Amplificati... EGF-R Positive ...	LMV-12(HE003)	18 Years -	Hunan Province Tumor Hospital
Continued Access to RXDX-105	NCT03784378	Non Small Cell ... Ovarian Cancer RET Gene Mutati... BRAF Gene Mutat...	RXDX-105	18 Years -	Memorial Sloan Kettering Cancer Center
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors	NCT03037385	RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise...	pralsetinib (BL...	18 Years -	Hoffmann-La Roche
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies	NCT05370469	Lung Cancer EGFR Gene Mutat... EGFR ALK Gene Mutati... RET Gene Mutati... MET Gene Mutati... KRAS Mutation-R... BRAF ROS1 Gene Mutat...	Sensus Smartwat... RX Cap Fitbit Sense Surveys	18 Years -	University of Virginia
Ponatinib in Advanced NSCLC w/ RET Translocations	NCT01813734	Non Small Cell ...	Ponatinib	18 Years -	Massachusetts General Hospital
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC	NCT06109558	Non Small Cell ... RET Gene Mutati... MET Amplificati... EGF-R Positive ...	LMV-12(HE003)	18 Years -	Hunan Province Tumor Hospital

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: